


## PHARMACEUTICAL 2019



## Organogenesis Holdings Inc. Rank 184 of 371





## PHARMACEUTICAL 2019



## Organogenesis Holdings Inc. Rank 184 of 371

The relative strengths and weaknesses of Organogenesis Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Organogenesis Holdings Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 423% points. The greatest weakness of Organogenesis Holdings Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 179% points.

The company's Economic Capital Ratio, given in the ranking table, is -151%, being 180% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	71,131
Cost of Goods Sold	68,808
Intangible Assets	51,630
Liabilities, Current	66,388
Liabilities, Non-Current	903
Other Assets	1,294
Other Compr. Net Income	0
Other Expenses	3,578
Other Liabilities	49,346
Other Net Income	-13,191
Property and Equipment	39,623
Research and Development	10,742
Revenues	193,449
Selling, General and Administrative Expense	161,961

Output Variable	Value in 1000 USD
Assets	163,678
Liabilities	116,637
Expenses	245,089
Stockholders Equity	47,041
Net Income	-64,831
Comprehensive Net Income	-64,831
Economic Capital Ratio	-151%